Abstract
HIV is known to have the ability to adapt rapidly its genome under drug pressure, resulting in clinical treatment failure. We present the case of an HIV-infected patient who developed mutations of resistance to nevirapine although he always had an undetectable viral load and without context of inobservance. The concepts of undetectability and virological success in HIV infection must be balanced by the possible appearance of resistance under a treatment considered as effective.
Keywords: HIV, drug resistance, nevirapine, viral load, HAART, virological efficacy, threshold, saquinavir, immunovirologic treatment, plasma HIV RNA
Current HIV Research
Title: Letter to the Editor [HIV Drug Resistance on HAART Despite an Undetectable Viral Load]
Volume: 9 Issue: 8
Author(s): Pierre Loulergue, Constance Delaugerre, Vincent Jullien and Jean-Paul Viard
Affiliation:
Keywords: HIV, drug resistance, nevirapine, viral load, HAART, virological efficacy, threshold, saquinavir, immunovirologic treatment, plasma HIV RNA
Abstract: HIV is known to have the ability to adapt rapidly its genome under drug pressure, resulting in clinical treatment failure. We present the case of an HIV-infected patient who developed mutations of resistance to nevirapine although he always had an undetectable viral load and without context of inobservance. The concepts of undetectability and virological success in HIV infection must be balanced by the possible appearance of resistance under a treatment considered as effective.
Export Options
About this article
Cite this article as:
Loulergue Pierre, Delaugerre Constance, Jullien Vincent and Viard Jean-Paul, Letter to the Editor [HIV Drug Resistance on HAART Despite an Undetectable Viral Load], Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998817
DOI https://dx.doi.org/10.2174/157016211798998817 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers